Rhodiola (Rhodiola rosea)
Rhodiola rosea is a high-altitude perennial of the Crassulaceae family with long traditional use in Russian, Scandinavian, and Tibetan herbal practice as an adaptogen. Sold in the UK as a food supplement (no authorised health claims) and via the separate THMP regulatory pathway (where THMP wording can appear). Standardisation by salidroside + rosavins is the quality marker. Pregnancy: avoid.
Camden Medicals editorial · Last reviewed 3 May 2026 · Next review November 2026
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Botanical
- Typical daily dose
- Trials of standardised SHR-5 / rhodiola extract have used 200–600 mg/day across 4–8 weeks (3% rosavins / 1% salidroside). Camden NB-537 supplies 125 mg of rhodiola extract per 2-capsule serving (3% rosavins / 1% salidroside) — at the lower end of the trial range, in a multi-active stack.
- Top use evidence
- Limited
On this page
What it is
Rhodiola rosea is a perennial flowering plant of the Crassulaceae family, native to high-altitude cold regions of the Arctic, Northern Europe, Russia, Central Asia, and parts of North America. It grows in rocky terrain at elevations of 1,000–5,000 metres. The medicinal part is the rhizome and root, traditionally harvested in late summer after the plant has flowered.
Common names include roseroot, golden root, arctic root, aaron's rod, and king's crown. The Sami people of Scandinavia used it traditionally for endurance during long expeditions; Russian folk medicine used it as a tonic for fatigue and weakness, with formal pharmacological investigation beginning in the Soviet era. Modern Western scientific interest dates to the 1990s and continues with both food-supplement and traditional-herbal-medicinal-product (THMP) commercial routes.
The bioactive compounds most studied are salidroside (a glycoside also called rhodioloside), rosavin and related rosavin-family glycosides (rosin, rosarin, rosiridin), and p-tyrosol. Modern clinical trials have used extracts standardised to 1% salidroside and 3% rosavins (the "rhodaxin" / SHR-5 profile, mirroring the wild Siberian root). Generic "rhodiola root powder" or unstandardised extracts at the same milligram label deliver an undeclared bioactive content and are not directly comparable to the trial materials.
Regulatory note: Rhodiola has a dual regulatory status in the UK. As a FOOD SUPPLEMENT it is lawful to retail; no UK food- supplement health claims are authorised (botanicals on EFSA hold). As a TRADITIONAL HERBAL MEDICINAL PRODUCT (THMP) it is regulated by the MHRA under the simplified registration scheme for traditional herbals — products with a granted THR (Traditional Herbal Registration) can use specified traditional-use claim wording on label and PDP. The two regulatory pathways do not cross. Camden NB-537 is a food supplement, not a THMP, and so cannot use THMP-pathway claim wording.
At a glance
- A perennial flowering plant (Rhodiola rosea, golden root) of high-altitude cold regions; long traditional adaptogen use.
- No UK-authorised food-supplement health claims. Botanicals on EFSA hold. EMA HMPC traditional-herbal-medicinal-product (THMP) monograph for stress / fatigue exists — that is a separate regulatory pathway, NOT applicable to food supplements.
- Quality marker: salidroside (≥1%) + rosavins (≥3%) standardisation by HPLC; the classical 3:1 rosavins:salidroside ratio mirrors wild Siberian root.
- Trial benefit signals (perceived stress, mental fatigue) emerge in 4–8 weeks of daily use, not acutely.
- Pregnancy: avoid. Theoretical MAO-inhibition activity at higher doses → talk to prescriber if you take any antidepressant.
What people use it for
Adults exploring supplements alongside lifestyle measures for self-reported stress / mental fatigue
Small RCTs of standardised rhodiola extract (typically 200–400 mg/day of 3% rosavins / 1% salidroside) across 4–8 weeks have reported modest reductions in self-reported stress / mental-fatigue scale scores. UK food-supplement claims are not authorised. UK NHS pathways for stress, anxiety, and depression apply (NICE CG113 anxiety, NG222 depression). [6]
Some evidenceLimitedAdults considering rhodiola for diagnosed depression, anxiety, or chronic fatigue syndrome
Rhodiola is not a UK NHS / NICE pathway for any of these. NICE NG222 lists depression management, CG113 anxiety / panic, NG206 ME/CFS. Self-supplementation in place of formal management is not appropriate. Talk to your GP. [1,6]
Popular, not provenInsufficientAdults with cognitive-fatigue endpoints (shift work, exam-period stress)
Small short trials in shift-workers and student populations have reported some endpoints in self-reported mental fatigue and reaction-time tests. Trial sizes are small. UK food-supplement claims for cognitive function from rhodiola are not authorised.
Some evidenceLimitedAdults using a UK-registered THMP rhodiola product
A THMP product carries MHRA-granted Traditional Herbal Registration and can use specified traditional-use claim wording. Camden NB-537 is a FOOD SUPPLEMENT and does not have THMP status — its PDP narration does not invoke THMP claim language even where rhodiola is an active.
Popular, not provenInsufficientAdults exploring traditional Russian / Scandinavian / Tibetan herbal practice
Long traditional-use history. Traditional-use framing is permissible on a food supplement; specific UK food-supplement health claims are not authorised.
Some evidenceLimited
How it works
Salidroside and rosavins have been studied for HPA-axis modulation (cortisol response in stressed adults), monoamine oxidase (MAO-A and MAO-B) inhibition in vitro and at higher doses in vivo, and direct effects on serotonergic and noradrenergic signalling. The net effect in trials is most consistently reported on self-reported stress / mental-fatigue scales over 4–8 weeks of daily use.
Common myths
Myth"Rhodiola is a "natural antidepressant""
RealityRhodiola is not a UK-licensed antidepressant and is not on UK NICE pathways for depression (NG222). Some small trials have reported reductions in self-reported HAM-D scores; NICE pathways list licensed pharmacological options, talking therapies, and exercise as recognised treatments. The "natural antidepressant" framing is marketing language, not clinical equivalence. [1]
Myth"Rhodiola gives you energy like caffeine"
RealityMechanism, time-course, and effect size differ from caffeine. Rhodiola has modest, chronic-use effects on self-reported mental fatigue scales over weeks; caffeine has acute (~30-minute) stimulant effects via adenosine receptor antagonism. The two are not comparable as "energiser" supplements.
Myth"Higher rhodiola doses are always better"
RealityTrial doses of 200–600 mg/day of standardised extract are the working range. Higher doses bring rising adverse-event rates, including mood-activation / irritability and possible sleep disruption (rhodiola is often described as activating; evening dosing can disrupt sleep in some individuals).
Myth"Rhodiola is safe to combine with any antidepressant"
RealityTheoretical MAO-inhibition activity + possible additive serotonergic / noradrenergic effects make this a prescriber-disclosure scenario. Talk to your prescribing GP or pharmacist before combining with any SSRI / SNRI / MAOI / tricyclic / atypical antidepressant.
Myth"Generic "rhodiola powder" is the same as standardised SHR-5"
RealityThe bioactive content is what the trial literature uses as a comparison anchor. Generic root powder or unstandardised X:1 extracts at the same milligram label deliver undeclared salidroside and rosavin content. Standardisation by salidroside + rosavins percentage by HPLC is the relevant quality marker.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Rhodiola (Rhodiola rosea). Each answer is editorial and links to its evidence in the Sources list below.
How long does rhodiola take to work?
The published trials report effects emerging at 2–8 weeks of daily use, with most stress and fatigue endpoints assessed at 4–8 weeks. There is no reliable single-dose acute effect. If you don''t notice anything in the first days, that is consistent with the trial protocols; reassess at 4–8 weeks or stop.
SHR-5 vs generic rhodiola extract — does it matter?
For trial-comparable supplementation, the standardised extracts are what the literature has used. SHR-5 (developed by the Swedish Herbal Institute) is standardised to 3% rosavins and 1% salidroside, mirroring the wild Siberian root profile. Generic "rhodiola root powder" or unstandardised X:1 extracts at the same milligram label deliver an undeclared bioactive content and are not directly comparable to the trial materials. Camden NB-537 declares 3% rosavins / 1% salidroside on the rhodiola component.
Can I take rhodiola if I take an antidepressant?
Talk to your prescriber first. Rhodiola has theoretical MAO-inhibition activity at higher doses (in vitro and animal-study evidence; clinical-dose in vivo data is limited). Combination with SSRIs (sertraline, fluoxetine, citalopram, etc.), SNRIs, MAOIs, tricyclics, or atypical antidepressants is not advised without prescriber oversight. The mechanism overlaps with the serotonin- syndrome concern that applies to other serotonergic supplements (5-HTP, St John''s Wort).
Can I take rhodiola while pregnant or breastfeeding?
No. Standard advice is to avoid rhodiola in pregnancy and lactation. There is limited human safety data and the HPA-axis modulation activity is a reason for conservative positioning. The Camden NB-537 label specifies adults only and carries the pregnancy contraindication.
Will rhodiola help with my chronic fatigue / ME-CFS?
Rhodiola is not on UK NICE pathways for ME/CFS (NG206). Self-supplementation for diagnosed ME/CFS is not the recognised pathway. Talk to your GP for assessment and management — recognised approaches include energy management / pacing, cognitive-behavioural therapy (CBT), and graded exercise where appropriate to the individual.
Is there a difference between THMP rhodiola and food-supplement rhodiola?
Yes — different regulatory routes. THMP (Traditional Herbal Medicinal Product) is a simplified MHRA registration scheme; THMP-registered rhodiola products carry a THR (Traditional Herbal Registration) number and can use specified traditional-use claim wording on label. Food-supplement rhodiola is regulated under the food-law framework; no health claims are permitted on the food-supplement form. Camden NB-537 is a food supplement, not a THMP.
⚖️ The official position
What may lawfully be claimed about Rhodiola (Rhodiola rosea) in Great Britain. This is a regulatory position, not an evidence grade.
No health claim is authorised for this use in Great Britain.
Rhodiola (Rhodiola rosea) has a history of traditional use. Authorised health claims require a positive EFSA scientific opinion; none has been issued for this use.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Self-reported stress in healthy adults — chronic use
LimitedEvidencelimitedMultiple small RCTs of standardised SHR-5 / rhodiola extract (200–400 mg/day, 3% rosavins / 1% salidroside) across 4–8 weeks have reported reductions in self-reported stress / fatigue scale scores in healthy adults. Trial sizes are small and most-cited references include Darbinyan 2007, Olsson 2009, Shevtsov 2003. Independent replication is partial.
Mild-to-moderate depression — small trials
LimitedEvidencelimitedSmall short trials of rhodiola in mild-moderate depression have reported some self-reported endpoint changes. NICE NG222 lists licensed pharmacological options, talking therapies, and exercise as recognised pathways; rhodiola is not on that pathway. Mao 2015 (Phytomedicine) compared rhodiola to sertraline in a small adult trial — both reduced HAM-D scores; rhodiola less than sertraline but with fewer side effects. Independent replication is limited; no UK-authorised claim. [1]
Mental fatigue — short-term
LimitedEvidencelimitedSmall trials in students and shift-workers have reported improvements in self-reported mental fatigue and reaction-time tests across 2–4 weeks of supplementation. Trial sizes are small. UK food-supplement claims for cognitive function from rhodiola are not authorised.
EMA / HMPC THMP monograph — traditional use
MixedEvidencemixedThe European Medicines Agency Committee on Herbal Medicinal Products (HMPC) has published a monograph listing rhodiola root extract for traditional use in relief of symptoms of stress (such as fatigue and feeling of weakness). UK MHRA recognises THMP registrations on this basis. THMP products can use specified traditional- use wording on label and PDP. Food supplements cannot use THMP wording — the two pathways are separate.
Safety
Rhodiola is generally well-tolerated in healthy adults at standard supplement doses for short durations. Theoretical MAO-inhibition activity → talk to your prescriber if you take antidepressants. Pregnancy: avoid. Some users find evening dosing disrupts sleep — morning or early-afternoon dosing is the convention.
Talk to your pharmacist or GP first if you:
- You take any antidepressant — SSRI, SNRI, MAOI, tricyclic, atypical (mirtazapine, trazodone). Theoretical additive serotonergic / noradrenergic effects.
- You take diabetes medication — possible blood-sugar lowering reported in animal studies.
- You take antihypertensives — possible additive BP-lowering in some trials.
- You take anticoagulants — limited interaction data; theoretical concern.
- You take immunosuppressants — limited data.
- You are pregnant, breastfeeding, or trying to conceive — avoid.
- You are under 18 — avoid as a standardised supplement.
- You have an active mood disorder — diagnosed depression, anxiety, bipolar — UK NHS / NICE pathways apply.
Common side effects: Generally well-tolerated. Some users report mood-activation / irritability or sleep disruption with evening dosing. GI complaints are uncommon.
Pregnancy and breastfeeding
Avoid. Limited human pregnancy safety data; the HPA-axis modulation activity is a reason for conservative positioning.
Avoid. Limited human lactation safety data.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Pregnancy — avoid (limited safety data; HPA-axis activity).
- Lactation — avoid (limited safety data).
- Paediatric use — avoid as a standardised supplement.
- Active bipolar disorder — relative contraindication; mood-activation potential.
- Known hypersensitivity to Crassulaceae-family plants.
Drug interactions
- SSRIs / SNRIs — possible additive serotonergic effects; theoretical MAO-inhibition activity.
- MAOIs (phenelzine, moclobemide) — avoid combination given rhodiola's own MAO-inhibition activity.
- Tricyclic antidepressants — possible additive effects; talk to prescriber.
- Antidiabetic medication — possible additive blood-sugar lowering in animal-study and small-trial data.
- Antihypertensives — possible additive BP-lowering.
- Anticoagulants / antiplatelets — limited interaction data; theoretical.
- Sedatives / hypnotics — possible interference; some users report rhodiola is activating.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mood-activation / irritability — can occur particularly at higher doses or in sensitive individuals.
- Sleep disruption — when taken in the evening; morning or early-afternoon dosing is the convention.
Rare side effects
- GI complaints — nausea, abdominal discomfort.
- Allergic reaction.
- Headache.
- Hypotension at higher doses.
How to take it
- Typical supplemental range
- Trials of standardised SHR-5 / rhodiola extract have used 200–600 mg/day across 4–8 weeks (3% rosavins / 1% salidroside). Camden NB-537 supplies 125 mg of rhodiola extract per 2-capsule serving (3% rosavins / 1% salidroside) — at the lower end of the trial range, in a multi-active stack.
- Timing
- Daily, ideally morning or early afternoon (some users find rhodiola activating; evening dosing can disrupt sleep). Effects emerge over 4–8 weeks of daily use; acute effects are not the trial endpoint.
How to spot quality
Look for
- Standardisation declared: rosavins percentage AND salidroside percentage by HPLC (typical: 3% rosavins / 1% salidroside; the SHR-5 profile).
- Plant species: Rhodiola rosea specifically (not Rhodiola crenulata or Rhodiola sacra, which have different bioactive profiles and are sometimes substituted).
- Plant part: rhizome / root preferred (the part used in the trial literature).
- Solvent / extraction method declared (water-ethanol is the trial-comparable form).
- Branded research-grade preparation (SHR-5 is the most-trialled).
- Country of cultivation declared (Russia / Siberia, Scandinavia, China are principal sources).
- Heavy-metal screening disclosed.
- Pregnancy contraindication on label.
- For UK regulated trade: distinction between THMP-registered (MHRA THR number) and food-supplement form, with PDP / label wording matched to the regulatory route.
Red flags
- Generic "rhodiola root powder" or "Rhodiola rosea extract" without rosavin / salidroside percentages.
- X:1 extract ratios marketed as potency without HPLC standardisation.
- Wrong species substitution (R. crenulata, R. sacra labelled as R. rosea).
- Marketing as "natural antidepressant" or "Rhodiola = mood medicine".
- Caffeine-equivalence framing (different mechanism, different time-course).
- No serotonergic-medication interaction warning.
- No pregnancy contraindication.
- Marketing of food-supplement form using THMP-pathway claim wording.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Ashwagandha (Withania somnifera)
Limited evidenceTwo adaptogens with overlapping HPA-axis cortisol-modulation framing; conventional in adaptogen stacks.
Both rhodiola (salidroside, rosavins) and ashwagandha (withanolides) have been studied for HPA-axis cortisol modulation. Mechanistic framing partially overlaps; outcome-trial evidence for the combination as such is limited. Camden NB-537 includes both at doses below the individual trial-comparable dose for each.
Evidence: Conventional in adaptogen stacks. Camden NB-537 supplies 125 mg rhodiola + 125 mg KSM-66 ashwagandha per 2-cap serving. Combination outcome trials are sparse.
Doses studied: Rhodiola 200–400 mg + ashwagandha 300–600 mg daily.
Found in Camden: Aurifera™ Shilajit Adaptogen Complex 90 Capsules